Advanced search
Publication Cover
Future Virology Volume 6, 2011 - Issue 4
Submit an article Journal homepage
71
Views
0
CrossRef citations to date
0
Altmetric
Review

Pathogenesis and Treatment of Human Immunodeficiency Virus-Associated Cytomegalovirus Retinitis

Suiyi Tan1 School of Pharmaceutical Sciences, Southern Medical University, Guangzhou510515, China. [email protected];2 Viral Immunology Laboratory, Lindsley F Kimball Research Institute, New York Blood Center, New York, NY10065, USA
,
Shuwen Liu1 School of Pharmaceutical Sciences, Southern Medical University, Guangzhou510515, China. [email protected]
&
Shibo Jiang1 School of Pharmaceutical Sciences, Southern Medical University, Guangzhou510515, China. [email protected];2 Viral Immunology Laboratory, Lindsley F Kimball Research Institute, New York Blood Center, New York, NY10065, USA;3 Key Laboratory of Medical Molecular Virology of MOE/MOH & Institute of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai200032, China
Pages 503-520 | Published online: 04 May 2011

Bibliography

  • Lane HC : Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation.Top. HIV Med.18(1) , 2–6 (2010).
  • Vrisekoop N , MandlJN, GermainRN: Life and death as a T lymphocyte: from immune protection to HIV pathogenesis.J. Biol.8(10) , 91 (2009).
  • Revello MG , GernaG: Pathogenesis and prenatal diagnosis of human cytomegalovirus infection.J. Clin. Virol.29(2) , 71–83 (2004).
  • Gerna G , BaldantiF, RevelloMG: Pathogenesis of human cytomegalovirus infection and cellular targets.Hum. Immunol.65(5) , 381–386 (2004).
  • Steininger C : Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system.Clin. Microbiol. Infect.13(10) , 953–963 (2007).
  • Sinclair J , Sissons P: Latency and reactivation of human cytomegalovirus. J. Gen. Virol.87(Pt 7) , 1763–1779 (2006).
  • Kempen JH , JabsDA, WilsonLA, DunnJP, WestSK: Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis.Am. J. Ophthalmol.139(6) , 1028–1034 (2005).
  • Jabs DA , Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD: Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology114(4) , 780–786 (2007).
  • Lai TY , WongRL, LukFO, ChowVW, ChanCK, LamDS: Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era.Clin. Exp. Ophthalmol.39(2) , 99–104 (2011).
  • Puhan MA , Van Natta ML, Palella FJ, Addessi A, Meinert C: Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin. Infect. Dis.51(8) , 947–956 (2010).
  • Jabs DA , Van Natta ML, Thorne JE et al.: Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology111(12) , 2224–2231 (2004).
  • Kempen JH , MartinBK, WuAW, BarronB, ThorneJE, JabsDA: The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy.Ophthalmology110(5) , 987–995 (2003).
  • Gharai S , VenkateshP, GargS, SharmaSK, VohraR: Ophthalmic manifestations of HIV infections in India in the era of HAART: analysis of 100 consecutive patients evaluated at a tertiary eye care center in India.Ophthalmic Epidemiol.15(4) , 264–271 (2008).
  • Palestine AG : Clinical aspects of cytomegalovirus retinitis.Rev. Infect. Dis.10(Suppl. 3) , S515–S521 (1988).
  • Bowen EF , WilsonP, AtkinsM et al.: Natural history of untreated cytomegalovirus retinitis.Lancet346(8991–8992) , 1671–1673 (1995).
  • Smith IL , MacdonaldJC, FreemanWR, ShapiroAM, SpectorSA: Cytomegalovirus (CMV) retinitis activity is accurately reflected by the presence and level of CMV DNA in aqueous humor and vitreous.J. Infect. Dis.179(5) , 1249–1253 (1999).
  • Thorne JE , JabsDA, KempenJH, HolbrookJT, NicholsC, MeinertCL: Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy.Ophthalmology113(8) , 1432–1440 (2006).
  • Gona P , Van Dyke RB, Williams PL et al.: Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA296(3) , 292–300 (2006).
  • Livingston PG , KerrNC, SullivanJL: Ocular disease in children with vertically acquired human immunodeficiency virus infection.J. AAPOS2(3) , 177–181 (1998).
  • Du LT , CoatsDK, KlineMW et al.: Incidence of presumed cytomegalovirus retinitis in HIV-infected pediatric patients.J. AAPOS3(4) , 245–249 (1999).
  • Scholz M , DoerrHW, CinatlJ: Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence.Trends Microbiol.11(4) , 171–178 (2003).
  • Skolnik PR , PomerantzRJ, de la Monte SM et al.: Dual infection of retina with human immunodeficiency virus type 1 and cytomegalovirus. Am. J. Ophthalmol.107(4) , 361–372 (1989).
  • Rummelt V , RummeltC, JahnG et al.: Triple retinal infection with human immunodeficiency virus type 1, cytomegalovirus, and herpes simplex virus type 1. Light and electron microscopy, immunohistochemistry, and in situ hybridization.Ophthalmology101(2) , 270–279 (1994).
  • Read RW , ZhangJA, IshimotoSI, RaoNA: Evaluation of the role of human retinal vascular endothelial cells in the pathogenesis of CMV retinitis.Ocul. Immunol. Inflamm.7(3–4) , 139–146 (1999).
  • Reeves M , SinclairJ: Aspects of human cytomegalovirus latency and reactivation.Curr. Top. Microbiol. Immunol.325 , 297–313 (2008).
  • Jackson SE , MasonGM, WillsMR: Human cytomegalovirus immunity and immune evasion.Virus Res. DOI:10.1016/j.virusres.2010.10.031 (2010) (Epub ahead of print).
  • Sinzger C , DigelM, JahnG: Cytomegalovirus cell tropism.Curr. Top. Microbiol. Immunol.325 , 63–83 (2008).
  • Rao NA , ZhangJ, IshimotoS: Role of retinal vascular endothelial cells in development of CMV retinitis.Trans. Am. Ophthalmol. Soc.96 , 111–123 (1998).
  • Smith MS , BentzGL, AlexanderJS, YurochkoAD: Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence.J. Virol.78(9) , 4444–4453 (2004).
  • Waldman WJ , KnightDA, HuangEH, SedmakDD: Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: an in vitro model.J. Infect. Dis.171(2) , 263–272 (1995).
  • Bentz GL , Jarquin-PardoM, ChanG, SmithMS, SinzgerC, YurochkoAD: Human cytomegalovirus (HCMV) infection of endothelial cells promotes naive monocyte extravasation and transfer of productive virus to enhance hematogenous dissemination of HCMV.J. Virol.80(23) , 11539–11555 (2006).
  • Zhang M , XinH, RoonP, AthertonSS: Infection of retinal neurons during murine cytomegalovirus retinitis.Invest. Ophthalmol. Vis. Sci.46(6) , 2047–2055 (2005).
  • Tugizov S , MaidjiE, PereiraL: Role of apical and basolateral membranes in replication of human cytomegalovirus in polarized retinal pigment epithelial cells.J. Gen. Virol.77(Pt 1) , 61–74 (1996).
  • Sugita S : Role of ocular pigment epithelial cells in immune privilege.Arch. Immunol. Ther. Exp. (Warsz.)57(4) , 263–268 (2009).
  • Bodaghi B , Slobbe-van Drunen ME, Topilko A et al.: Entry of human cytomegalovirus into retinal pigment epithelial and endothelial cells by endocytosis. Invest. Ophthalmol. Vis. Sci.40(11) , 2598–2607 (1999).
  • Ryckman BJ , JarvisMA, DrummondDD, NelsonJA, JohnsonDC: Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion.J. Virol.80(2) , 710–722 (2006).
  • Wang D , YuQC, SchroerJ, MurphyE, ShenkT: Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells.Proc. Natl Acad. Sci. USA104(50) , 20037–20042 (2007).
  • Ryckman BJ , RainishBL, ChaseMC et al.: Characterization of the human cytomegalovirus gH/gL/UL128–131 complex that mediates entry into epithelial and endothelial cells.J. Virol.82(1) , 60–70 (2008).
  • Ryckman BJ , ChaseMC, JohnsonDC: HCMV gH/gL/UL128–131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors.Proc. Natl Acad. Sci. USA105(37) , 14118–14123 (2008).
  • Wang D , ShenkT: Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism.J. Virol.79(16) , 10330–10338 (2005).
  • Wang D , ShenkT: Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.Proc. Natl Acad. Sci. USA102(50) , 18153–18158 (2005).
  • Maidji E , TugizovS, JonesT, ZhengZ, PereiraL: Accessory human cytomegalovirus glycoprotein US9 in the unique short component of the viral genome promotes cell-to-cell transmission of virus in polarized epithelial cells.J. Virol.70(12) , 8402–8410 (1996).
  • Pereira L , MaidjiE, TugizovS, JonesT: Deletion mutants in human cytomegalovirus glycoprotein US9 are impaired in cell-cell transmission and in altering tight junctions of polarized human retinal pigment epithelial cells.Scand. J. Infect. Dis. Suppl.99 , 82–87 (1995).
  • Kalejta RF : Functions of human cytomegalovirus tegument proteins prior to immediate early gene expression.Curr. Top. Microbiol. Immunol.325 , 101–115 (2008).
  • Adair R , LiebischGW, LermanBJ, Colberg-PoleyAM: Human cytomegalovirus temporally regulated gene expression in differentiated, immortalized retinal pigment epithelial cells.J. Clin. Virol.35(4) , 478–484 (2006).
  • Murphy E , VanicekJ, RobinsH, ShenkT, LevineAJ: Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency.Proc. Natl Acad. Sci. USA105(14) , 5453–5458 (2008).
  • Sinclair E , TanQX, SharpM et al.: Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon-γ and interleukin-2 and have a CD8+ cell early maturational phenotype.J. Infect. Dis.194(11) , 1537–1546 (2006).
  • Miller-Kittrell M , SparerTE: Feeling manipulated: cytomegalovirus immune manipulation.Virol. J.6 , 4 (2009).
  • Crough T , KhannaR: Immunobiology of human cytomegalovirus: from bench to bedside.Clin. Microbiol. Rev.22(1) , 76–98 (2009).
  • Momma Y , NagineniCN, ChinMS, SrinivasanK, DetrickB, HooksJJ: Differential expression of chemokines by human retinal pigment epithelial cells infected with cytomegalovirus.Invest. Ophthalmol. Vis. Sci.44(5) , 2026–2033 (2003).
  • Craigen JL , YongKL, JordanNJ et al.: Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration.Immunology92(1) , 138–145 (1997).
  • Cinatl J Jr, Blaheta R, Bittoova M et al.: Decreased neutrophil adhesion to human cytomegalovirus-infected retinal pigment epithelial cells is mediated by virus-induced up-regulation of Fas ligand independent of neutrophil apoptosis. J. Immunol.165(8) , 4405–4413 (2000).
  • Allart S , LuleJ, SerresB et al.: Impaired killing of HCMV-infected retinal pigment epithelial cells by anti-pp65 CD8+ cytotoxic T cells.Invest. Ophthalmol. Vis. Sci.44(2) , 665–671 (2003).
  • Lawrence T : The nuclear factor NF-κB pathway in inflammation.Cold Spring Harb. Perspect. Biol.1(6) , A001651 (2009).
  • Chan G , Bivins-SmithER, SmithMS, YurochkoAD: NF-κB and phosphatidylinositol 3-kinase activity mediates the HCMV-induced atypical M1/M2 polarization of monocytes.Virus Res.144(1–2) , 329–333 (2009).
  • Cinatl J Jr, Margraf S, Vogel JU, Scholz M, Cinatl J, Doerr HW: Human cytomegalovirus circumvents NF-κB dependence in retinal pigment epithelial cells. J. Immunol.167(4) , 1900–1908 (2001).
  • Liversidge J , McKayD, MullenG, ForresterJV: Retinal pigment epithelial cells modulate lymphocyte function at the blood–retina barrier by autocrine PGE2 and membrane-bound mechanisms.Cell. Immunol.149(2) , 315–330 (1993).
  • Zhu H , CongJP, YuD, BresnahanWA, ShenkTE: Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication.Proc. Natl Acad. Sci. USA99(6) , 3932–3937 (2002).
  • Schroer J , ShenkT: Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus.Proc. Natl Acad. Sci. USA105(49) , 19468–19473 (2008).
  • Chin MS , NagineniCN, HooperLC, DetrickB, HooksJJ: Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells.Invest. Ophthalmol. Vis. Sci.42(10) , 2338–2346 (2001).
  • Soderberg-Naucler C , NelsonJY: Human cytomegalovirus latency and reactivation – a delicate balance between the virus and its host‘s immune system.Intervirology42(5–6) , 314–321 (1999).
  • Sambucetti LC , CherringtonJM, WilkinsonGW, MocarskiES: NF-κB activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation.EMBO J.8(13) , 4251–4258 (1989).
  • Hunninghake GW , MonickMM, LiuB, StinskiMF: The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements.J. Virol.63(7) , 3026–3033 (1989).
  • Lang D , FickenscherH, StammingerT: Analysis of proteins binding to the proximal promoter region of the human cytomegalovirus IE-1/2 enhancer/promoter reveals both consensus and aberrant recognition sequences for transcription factors Sp1 and CREB.Nucleic Acids Res.20(13) , 3287–3295 (1992).
  • Kothari S , BaillieJ, SissonsJG, SinclairJH: The 21bp repeat element of the human cytomegalovirus major immediate early enhancer is a negative regulator of gene expression in undifferentiated cells.Nucleic Acids Res.19(8) , 1767–1771 (1991).
  • Liu R , BaillieJ, SissonsJG, SinclairJH: The transcription factor YY1 binds to negative regulatory elements in the human cytomegalovirus major immediate early enhancer/promoter and mediates repression in non-permissive cells.Nucleic Acids Res.22(13) , 2453–2459 (1994).
  • Zhang XY , InamdarNM, SupakarPC, WuK, EhrlichKC, EhrlichM: Three MDBP sites in the immediate-early enhancer-promoter region of human cytomegalovirus.Virology182(2) , 865–869 (1991).
  • Huang TH , OkaT, AsaiT et al.: Repression by a differentiation-specific factor of the human cytomegalovirus enhancer.Nucleic Acids Res.24(9) , 1695–1701 (1996).
  • Zweidler-Mckay PA , GrimesHL, FlubacherMM, TsichlisPN: Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor.Mol. Cell. Biol.16(8) , 4024–4034 (1996).
  • Bain M , MendelsonM, SinclairJ: Ets-2 Repressor factor (ERF) mediates repression of the human cytomegalovirus major immediate-early promoter in undifferentiated non-permissive cells.J. Gen. Virol.84(Pt 1) , 41–49 (2003).
  • Boomker JM , TheTH, de Leij LF, Harmsen MC: The human cytomegalovirus-encoded receptor US28 increases the activity of the major immediate-early promoter/enhancer. Virus Res.118(1–2) , 196–200 (2006).
  • Stein-Streilein J : Immune regulation and the eye.Trends Immunol.29(11) , 548–554 (2008).
  • Chiou SH , YangYP, LinJC et al.: The immediate early 2 protein of human cytomegalovirus (HCMV) mediates the apoptotic control in HCMV retinitis through up-regulation of the cellular FLICE-inhibitory protein expression.J. Immunol.177(9) , 6199–6206 (2006).
  • Buggage RR , ChanCC, MattesonDM, ReedGF, WhitcupSM: Apoptosis in cytomegalovirus retinitis associated with AIDS.Curr. Eye Res.21(3) , 721–729 (2000).
  • Zamiri P , MasliS, KitaichiN, TaylorAW, StreileinJW: Thrombospondin plays a vital role in the immune privilege of the eye.Invest. Ophthalmol. Vis. Sci.46(3) , 908–919 (2005).
  • Cinatl J Jr, Bittoova M, Margraf S et al.: Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents. J. Infect. Dis.182(3) , 643–651 (2000).
  • Scholz M , VogelJU, HoverG et al.: Thrombin induces Sp1-mediated antiviral effects in cytomegalovirus-infected human retinal pigment epithelial cells.Med. Microbiol. Immunol.193(4) , 195–203 (2004).
  • Scholz M , VogelJU, HoverG et al.: Thrombin stimulates IL-6 and IL-8 expression in cytomegalovirus-infected human retinal pigment epithelial cells.Int. J. Mol. Med.13(2) , 327–331 (2004).
  • Koevary SB : Ocular immune privilege: a review.Clin. Eye Vis. Care12(3–4) , 97–106 (2000).
  • Helantera I , TeppoAM, KoskinenP, TornrothT, Gronhagen-RiskaC, LautenschlagerI: Increased urinary excretion of transforming growth factor-β(1) in renal transplant recipients during cytomegalovirus infection.Transpl. Immunol.15(3) , 217–221 (2006).
  • Helantera I , LoginovR, KoskinenP, TornrothT, Gronhagen-RiskaC, LautenschlagerI: Persistent cytomegalovirus infection is associated with increased expression of TGF-β1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts.Nephrol. Dial. Transplant.20(4) , 790–796 (2005).
  • Trujillo JR , Jaramillo-RangelG, Ortega-MartinezM et al.: International NeuroAIDS: prospects of HIV-1 associated neurological complications.Cell Res.15(11–12) , 962–969 (2005).
  • Dunfee R , ThomasER, GorryPR, WangJ, AncutaP, GabuzdaD: Mechanisms of HIV-1 neurotropism.Curr. HIV Res.4(3) , 267–278 (2006).
  • Luo MH , SchwartzPH, FortunatoEA: Neonatal neural progenitor cells and their neuronal and glial cell derivatives are fully permissive for human cytomegalovirus infection.J. Virol.82(20) , 9994–10007 (2008).
  • Tsutsui Y , KosugiI, KawasakiH: Neuropathogenesis in cytomegalovirus infection: indication of the mechanisms using mouse models.Rev. Med. Virol.15(5) , 327–345 (2005).
  • Cheeran MC , LokensgardJR, SchleissMR: Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.Clin. Microbiol. Rev.22(1) , 99–126 (2009).
  • Noyola DE , Jiménez-CapdevilleME, Demmler-HarrisonGJ: Central nervous system disorders in infants with congenital cytomegalovirus infection.Neurol. Res.32(3) , 278–284 (2010).
  • Skolnik PR , KosloffBR, HirschMS: Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus.J. Infect. Dis.157(3) , 508–514 (1988).
  • Griffiths PD : CMV as a cofactor enhancing progression of AIDS.J. Clin. Virol.35(4) , 489–492 (2006).
  • Kim A , DadgostarH, HollandGN et al.: Hemorheologic abnormalities associated with HIV infection: altered erythrocyte aggregation and deformability.Invest. Ophthalmol. Vis. Sci.47(9) , 3927–3932 (2006).
  • Dadgostar H , HollandGN, HuangX et al.: Hemorheologic abnormalities associated with HIV infection: in vivo assessment of retinal microvascular blood flow.Invest. Ophthalmol. Vis. Sci.47(9) , 3933–3938 (2006).
  • Kozak I , BartschDU, ChengL, KosobuckiBR, FreemanWR: Objective analysis of retinal damage in HIV-positive patients in the HAART era using OCT.Am. J. Ophthalmol.139(2) , 295–301 (2005).
  • Nakamuta S , EndoH, HigashiY et al.: Human immunodeficiency virus type 1 gp120-mediated disruption of tight junction proteins by induction of proteasome-mediated degradation of zonula occludens-1 and -2 in human brain microvascular endothelial cells.J. Neurovirol.14(3) , 186–195 (2008).
  • Prosch S , WendtCE, ReinkeP et al.: A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation.Virology272(2) , 357–365 (2000).
  • Ironson G , KremerH: Spiritual transformation, psychological well-being, health, and survival in people with HIV.Int. J. Psychiatry Med.39(3) , 263–281 (2009).
  • Deghaide NH , RodriguesML, CastelliEC, Mendes-JuniorCT, FigueiredoJF, DonadiEA: Tumor necrosis factor region polymorphisms are associated with AIDS and with cytomegalovirus retinitis.AIDS23(13) , 1641–1647 (2009).
  • Macdonald JC , KaravellasMP, TorrianiFJ et al.: Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis.Ophthalmology107(5) , 877–881 (2000).
  • Waib LF , BononSH, SallesAC et al.: Withdrawal of maintenance therapy for cytomegalovirus retinitis in AIDS patients exhibiting immunological response to HAART.Rev. Inst. Med. Trop. Sao Paulo49(4) , 215–219 (2007).
  • Lurain NS , ChouS: Antiviral drug resistance of human cytomegalovirus.Clin. Microbiol. Rev.23(4) , 689–712 (2010).
  • Chou S : Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.Rev. Med. Virol.18(4) , 233–246 (2008).
  • Kappel PJ , CharonisAC, HollandGN et al.: Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis.Ophthalmology113(4) , 683–688 (2006).
  • Musch DC , MartinDF, GordonJF, DavisMD, KuppermannBD: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.N. Engl. J. Med.337(2) , 83–90 (1997).
  • Roth DB , FeuerWJ, BlenkeAJ, DavisJL: Treatment of recurrent cytomegalovirus retinitis with the ganciclovir implant.Am. J. Ophthalmol.127(3) , 276–282 (1999).
  • Patil AJ , SharmaA, KenneyMC, KuppermannBD: Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.Clin. Ophthalmol.4 , 111–119 (2010).
  • Cvetkovic RS , WellingtonK: Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.Drugs65(6) , 859–878 (2005).
  • Jouan M , KatlamaC: Management of CMV retinitis in the era of highly active antiretroviral therapy.Int. J. Antimicrob. Agents13(1) , 1–7 (1999).
  • Song MK , AzenSP, BuleyA et al.: Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis.Am. J. Ophthalmol.136(4) , 696–702 (2003).
  • Kirsch LS , ArevaloJF, Chavez de la Paz E, Munguia D, De CE, Freeman WR: Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology102(4) , 533–542 (1995).
  • Rahhal FM , ArevaloJF, MunguiaD et al.: Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis.Ophthalmology103(7) , 1078–1083 (1996).
  • Stewart MW : Optimal management of cytomegalovirus retinitis in patients with AIDS.Clin. Ophthalmol.4 , 285–299 (2010).
  • Heiden D , FordN, WilsonD et al.: Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic.PLOS Med.4(12) , E334 (2007).
  • Teerawattananon K , IewsakulS, YenjitrC et al.: Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study.Pharmacoeconomics25(5) , 413–428 (2007).
  • Young S , McCluskeyP, MinassianDC et al.: Retinal detachment in cytomegalovirus retinitis: intravenous versus intravitreal therapy.Clin. Exp. Ophthalmol.31(2) , 96–102 (2003).
  • Visser L : Managing CMV retinitis in the developing world.Community Eye Health16(47) , 38–39 (2003).
  • Mahadevia PJ , GeboKA, PettitK, DunnJP, CovingtonMT: The epidemiology, treatment patterns, and costs of cytomegalovirus retinitis in the post-HAART era among a national managed-care population.J. Acquir. Immune Defic. Syndr.36(4) , 972–977 (2004).
  • Duvvuri S , JanoriaKG, PalD, MitraAK: Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,l-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.J. Ocul. Pharmacol. Ther.23(3) , 264–274 (2007).
  • Peng YJ , WenCW, ChiouSH, LiuSJ: Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis.Biomaterials31(7) , 1773–1779 (2010).
  • Lilleri D , PiccininiG, BaldantiF, SeminariE, GalloniD, GernaG: Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response.J. Clin. Virol.26(1) , 95–100 (2003).
  • Jabs DA , MartinBK, FormanMS et al.: Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis.Am. J. Ophthalmol.135(1) , 26–34 (2003).
  • Jabs DA , MartinBK, FormanMS: Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.Ophthalmology117(1) , 128–132 (2010).
  • Schrier RD , SongMK, SmithIL et al.: Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis.Retina26(2) , 165–169 (2006).
  • Ortega-Larrocea G , EspinosaE, Reyes-TeránG: Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy.AIDS19(7) , 735–738 (2005).
  • Browne EP , ShenkT: Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells.Proc. Natl Acad. Sci. USA100(20) , 11439–11444 (2003).
  • Jenkins C , AbendrothA, SlobedmanB: A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection.J. Virol.78(3) , 1440–1447 (2004).
  • van Cleef KW , SmitMJ, BruggemanCA, VinkC: Cytomegalovirus-encoded homologs of G protein-coupled receptors and chemokines.J. Clin. Virol.35(3) , 343–348 (2006).
  • Beisser PS , LavreysenH, BruggemanCA, VinkC: Chemokines and chemokine receptors encoded by cytomegaloviruses.Curr. Top. Microbiol. Immunol.325 , 221–242 (2008).
  • Millar AB , MillerRF, PatouG, MindelA, MarshR, SempleSJ: Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity.Genitourin. Med.66(3) , 156–158 (1990).
  • Martin DF , Sierra-MaderoJ, WalmsleyS et al.: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.N. Engl. J. Med.346(15) , 1119–1126 (2002).
  • Katlama C : Management of CMV retinitis in HIV infected patients.Genitourin. Med.73(3) , 169–173 (1997).
  • Gerard L , Salmon-CeronD: Pharmacology and clinical use of foscarnet.Int. J. Antimicrob. Agents5(4) , 209–217 (1995).
  • Jacobson MA : Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.N. Engl. J. Med.337(2) , 105–114 (1997).
  • Biron KK : Antiviral drugs for cytomegalovirus diseases.Antiviral Res.71(2–3) , 154–163 (2006).
  • Bourges JL , BloquelC, ThomasA et al.: Intraocular implants for extended drug delivery: therapeutic applications.Adv. Drug Deliv. Rev.58(11) , 1182–1202 (2006).
  • Shane TS , MartinDF: Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis.Am. J. Ophthalmol.136(4) , 649–654 (2003).
  • Dunn JP , VanNM, FosterG et al.: Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial.Retina24(1) , 41–50 (2004).
  • Guembel HO , KrieglsteinerS, RosenkranzC, HattenbachLO, KochFH, OhrloffC: Complications after implantation of intraocular devices in patients with cytomegalovirus retinitis.Graefes Arch. Clin. Exp. Ophthalmol.237(10) , 824–829 (1999).
  • Vitravene Study Group: Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am. J. Ophthalmol.133(4) , 475–483 (2002).
  • de Smet MD , MeenkenCJ, van den Horn GJ: Fomivirsen – a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm.7(3–4) , 189–198 (1999).
  • Amin HI , AiE, McDonaldHR, JohnsonRN: Retinal toxic effects associated with intravitreal fomivirsen.Arch. Ophthalmol.118(3) , 426–427 (2000).
  • Stone TW , JaffeGJ: Reversible bull‘s-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis.Am. J. Ophthalmol.130(2) , 242–243 (2000).
  • Arevalo JF , GarciaRA, MendozaAJ: High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela.Eur. J. Ophthalmol.15(5) , 610–618 (2005).
  • Yutthitham K , RuamviboonsukP: The high-dose, alternate-week intravitreal ganciclovir injections for cytomegalovirus retinitis in acquired immune deficiency syndrome patients on highly active antiretroviral therapy.J. Med. Assoc. Thai.88(Suppl. 9) , S63–S68 (2005).
  • Ausayakhun S , YuvavesP, NgamtiphakomS, PrasitsilpJ: Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir.J. Med. Assoc. Thai.88(Suppl. 9) , S15–S20 (2005).
  • Choopong P , TesavibulN, RodanantN: Crystallization after intravitreal ganciclovir injection.Clin. Ophthalmol.4 , 709–711 (2010).
  • Lieberman RM , OrellanaJ, MeltonRC: Efficacy of intravitreal foscarnet in a patient with AIDS.N. Engl. J. Med.330(12) , 868–869 (1994).
  • Ausayakhun S , WatananikornS, NgamtiphakornS, PrasitsilpJ: Intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS.J. Med. Assoc. Thai.88(1) , 103–107 (2005).
  • Kirsch LS , ArevaloJF, DeCE et al.: Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.Am. J. Ophthalmol.119(4) , 466–476 (1995).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.